(NASDAQ: TLSI) Trisalus Life Sciences's forecast annual revenue growth rate of 39.67% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.7%.
Trisalus Life Sciences's revenue in 2025 is $35,990,000.On average, 2 Wall Street analysts forecast TLSI's revenue for 2025 to be $2,228,568,699, with the lowest TLSI revenue forecast at $2,208,123,114, and the highest TLSI revenue forecast at $2,249,014,283. On average, 2 Wall Street analysts forecast TLSI's revenue for 2026 to be $3,303,707,234, with the lowest TLSI revenue forecast at $3,116,704,938, and the highest TLSI revenue forecast at $3,490,709,530.
In 2027, TLSI is forecast to generate $5,093,942,550 in revenue, with the lowest revenue forecast at $5,093,942,550 and the highest revenue forecast at $5,093,942,550.